This website is for US healthcare professionals


Log In to Bolder Science


Don't have an account? Sign Up


Please enter your email address.

You will receive a link to create a new password via email.

Log In


Create an Account

  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Influence of Hyperbilirubinaemia on Two Different Near Infrared Spectroscopy Devices

  • identifier


  • Recruitment Status


  • First Posted

    May 10, 2019

  • Last update posted

    March 18, 2021

Study Description

Brief summary:

Protocol Near infrared spectroscopy liver transplants: comparison of two monitoring of Near infrared spectroscopy in pediatric liver transplant.

  • Condition or Disease:Liver Transplant; Complications
  • Intervention/Treatment: Device: Near infrared spectroscopy with INVOS device
    Device: Near infrared spectroscopy with Foresight device
  • Phase: N/A

Detailed Description

Hyperbilirubinaemia may interfere with oximetry values as measured by Near Infrared Spectroscopy devices. The number of wave lengths used by different devices can influence the oximetry values in adult patients. This has never been demonstrated in children with hyperbilirubinaemia scheduled for elective liver transplantation.The study will compare cerebral and somatic oximetry values measured by two different Near infrared spectroscopy devices (FORESIGHT and INVOS) and analyse the influence of bilirubin levels on these differences.

Study Design

  • Study Type: Interventional
  • Actual Enrollment: 33 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Other
  • Official Title: Influence of Hyperbilirubinaemia on Foresight and INVOS Oximetry Values in Pediatric Hepatic Transplantation
  • Actual Study Start Date: March 2019
  • Actual Primary Completion Date: October 2020
  • Actual Study Completion Date: October 2020

Arms and interventions

Arm Intervention/treatment
Other: Pediatric liver transplant patients
Using somatic and cerebral Near infrared spectroscopy devices
Device: Near infrared spectroscopy with INVOS device
somatic and cerebral oximetry by INVOS in pediatric liver transplantation

Device: Near infrared spectroscopy with Foresight device
somatic and cerebral oximetry with Foresight device in pediatric liver transplantation

Outcome Measures

  • Primary Outcome Measures: 1. influence of chromophores such as bilirubin on oximetry values provided by two different devices [ Time Frame: From Day 0 of surgery until arrival at pediatric intensive care unit (up to 12 hours) ]
    measure of oximetry values by two different devices at different time points in function of serum bilirubin levels

Eligibility Criteria

  • Ages Eligible for Study: up to 18 / (18 to 64 years)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No


Inclusion Criteria:

- Pediatric patients 0 to 18 years, with a liver transplant with living donor program of
our institution

- Free, informed and written consent signed by the investigator or employees and by the
legal guardians of minor patients in the days preceding the procedure

Exclusion Criteria:

- refusal of the patient or his parents to consent

- known brain or Neurological pathology

Contacts and Locations



Cliniques Universitaires Saint-Luc

Sponsors and Collaborators

Cliniques universitaires Saint-Luc- Université Catholique de Louvain


Principal Investigator: Natalia MAGASICH-AIROLA, MD

More Information

  • Responsible Party: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
  • Identifier: NCT03945942 History of Changes
  • Other Study ID Numbers: 2018/07NOV/413
  • First Posted: May 10, 2019 Key Record Dates
  • Last Update Posted: March 18, 2021
  • Last Verified: March 2021
  • Individual Participant
    Data (IPD) Sharing

  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Hyperbilirubinemia